Strangles continues to pose a serious threat to equine health, with outbreaks often spreading rapidly through stables and competition venues. While strict biosecurity measures have long been essential in controlling the disease, new European field data suggest that an innovative vaccine could offer an additional level of protection. Following the administration of 100,000 doses, researchers have reported encouraging results, with only a small number of confirmed infections among vaccinated horses.
A persistent threat to equine health
Caused by the highly contagious bacterium Streptococcus equi, strangles remains a major concern for horse owners and equestrian facilities worldwide. The infection can spread through direct contact between horses, but contaminated equipment, shared drinking facilities and clothing can also contribute to transmission.
Affected horses may develop high fever, swollen lymph nodes and painful abscesses, while more severe cases can lead to respiratory complications. Although many horses recover, the disease can have serious consequences and occasionally prove fatal.
European field data reveal encouraging findings
A vaccine developed using recombinant protein technology is now attracting attention following the publication of new real world findings from Europe.
The data, collected after the first 100,000 vaccine doses had been administered, revealed that 19 horses which had completed their primary vaccination course subsequently showed clinical signs consistent with strangles.
However, further diagnostic investigations confirmed Streptococcus equi infection in just three of those cases. Researchers reported an incidence of 0.006%, although the total number of doses administered does not necessarily correspond to the number of fully vaccinated horses.
What makes these findings particularly interesting is the level of exposure involved. Many of the vaccinated horses were kept at facilities where strangles outbreaks were already ongoing, placing them in environments with an elevated risk of infection.
Targeting the bacterium through multiple proteins
Unlike conventional approaches, the recombinant protein-based vaccine is designed to stimulate an immune response against several components of the bacterium.
By targeting specific proteins and antigens involved in the infection process, the vaccine aims to prepare the horse's immune system to recognise and respond to the pathogen more effectively.
The reported field results suggest that this approach could offer meaningful protection, although further comparative research is needed to establish its precise effectiveness.
Vaccination could strengthen existing biosecurity measures
For equestrian centres, breeding operations and competition facilities, the findings offer an encouraging perspective on disease prevention.
Vaccination could become a valuable addition to existing measures, particularly in environments where horses frequently come into contact with one another or where the risk of an outbreak is heightened.
Nevertheless, researchers emphasise the importance of maintaining appropriate biosecurity practices. Hygiene, monitoring and isolation of potentially infected horses remain essential components of strangles prevention.
Horse owners considering vaccination are advised to consult their veterinarian to determine how it could fit into their existing preventive health programme.
